ForPatients
by Roche

Post Traumatic Stress Disorder

Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)

Trial Status	Trial Runs In	Trial Identifier
Recruiting	1 Countries	NCT05401565 BN43546

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the efficacy and safety of 10 mg of oral administration balovaptan once a day (QD) compared with matching placebo in adults with PTSD.

Hoffmann-La Roche	Phase 2
Sponsor	Phase

NCT05401565 BN43546
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=18 Years & <= 60 Years	No